- Home
- HTBK vs MBX Comparison
HTBK vs MBX Comparison
Compare HTBK & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTBK
- MBX
- Stock Information
- Founded
- HTBK 1997
- MBX 36
- Country
- HTBK United States
- MBX United States
- Employees
- HTBK N/A
- MBX N/A
- Industry
- HTBK Major Banks
- MBX
- Sector
- HTBK Finance
- MBX
- Exchange
- HTBK Nasdaq
- MBX NYSE
- Market Cap
- HTBK 566.4M
- MBX 644.6M
- IPO Year
- HTBK 1998
- MBX 2024
- Fundamental
- Price
- HTBK $9.22
- MBX $9.89
- Analyst Decision
- HTBK Buy
- MBX Strong Buy
- Analyst Count
- HTBK 2
- MBX 4
- Target Price
- HTBK $11.75
- MBX $37.25
- AVG Volume (30 Days)
- HTBK 325.7K
- MBX 373.3K
- Earning Date
- HTBK 01-31-2025
- MBX 02-16-2025
- Dividend Yield
- HTBK 5.64%
- MBX N/A
- EPS Growth
- HTBK N/A
- MBX N/A
- EPS
- HTBK 0.71
- MBX N/A
- Revenue
- HTBK $169,172,000.00
- MBX N/A
- Revenue This Year
- HTBK N/A
- MBX N/A
- Revenue Next Year
- HTBK $5.68
- MBX N/A
- P/E Ratio
- HTBK $13.06
- MBX N/A
- Revenue Growth
- HTBK N/A
- MBX N/A
- 52 Week Low
- HTBK $7.66
- MBX $9.65
- 52 Week High
- HTBK $11.27
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- HTBK 40.20
- MBX N/A
- Support Level
- HTBK $9.07
- MBX N/A
- Resistance Level
- HTBK $9.29
- MBX N/A
- Average True Range (ATR)
- HTBK 0.24
- MBX 0.00
- MACD
- HTBK 0.03
- MBX 0.00
- Stochastic Oscillator
- HTBK 61.22
- MBX 0.00
About HTBK Heritage Commerce Corp
Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two segments, namely Banking and Factoring. The bank generates its revenue from the Banking segment.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.